Precision BioSciences Inc
NASDAQ:DTIL

Watchlist Manager
Precision BioSciences Inc Logo
Precision BioSciences Inc
NASDAQ:DTIL
Watchlist
Price: 6.86 USD -5.25% Market Closed
Market Cap: 52.6m USD
Have any thoughts about
Precision BioSciences Inc?
Write Note

Precision BioSciences Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Precision BioSciences Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Precision BioSciences Inc
NASDAQ:DTIL
Depreciation & Amortization
-$3.3m
CAGR 3-Years
24%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Precision BioSciences Inc
Glance View

Market Cap
51.3m USD
Industry
Biotechnology

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 198 full-time employees. The company went IPO on 2019-03-28. The company is developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. The firm's ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. Its subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.

DTIL Intrinsic Value
12.31 USD
Undervaluation 44%
Intrinsic Value
Price

See Also

What is Precision BioSciences Inc's Depreciation & Amortization?
Depreciation & Amortization
-3.3m USD

Based on the financial report for Sep 30, 2024, Precision BioSciences Inc's Depreciation & Amortization amounts to -3.3m USD.

What is Precision BioSciences Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-4%

Over the last year, the Depreciation & Amortization growth was 19%. The average annual Depreciation & Amortization growth rates for Precision BioSciences Inc have been 24% over the past three years , -4% over the past five years .

Back to Top